UK’s NICE will cov­er $700K cost of GSK’s gene ther­a­py; Evoke shares spike on NDA plans

→ The UK’s phar­ma price watch­dog NICE has sanc­tioned cov­er­age of Glax­o­SmithK­line’s gene ther­a­py Strimvelis for “bub­ble ba­by” syn­drome, which costs about $700,000 for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER